Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

22 March 2013

Treatment of Cytomegalovirus infection after renal transplantation: Experience from a Single Center in China

Yang LiABCDEFG, Hang YanACFG, Wu-Jun XueABCDG, Pu-Xun TianACF, Xiao-Ming DingACF, Xiao-Ming PanACF, Xin-Shun FengACF, He-Li XiangACF, Jun HouACF, Xiao-Hui TianACF, Jin ZhengCF, Chen-Guang DingCF, Ping FanCEFG, Hong-Bao LiuCF

DOI: 10.12659/AOT.883859

Ann Transplant 2013; 18:124-134

Abstract

BACKGROUND: We compared the efficacy and safety of 2 different treatments of CMV infection, including asymptomatic CMV replication and CMV disease.

MATERIAL AND METHODS: 852 renal transplantation recipients, including asymptomatic CMV replication and CMV disease, received antiviral therapies of intravenous acyclovir or comprehensive anti-infection solution, mainly with intravenous ganciclovir. Effect, time, acute allograft rejection, and safety were analyzed during the antiviral therapy

RESULTS: The total effective rates were higher with ganciclovir in both asymptomatic CMV replication (98.96% vs. 84.90%) and CMV disease (96.29% vs. 50.36%). Ganciclovir significantly shortened antiviral therapy duration in both asymptomatic CMV replication (15.0±2.3 days vs. 16.0±3.4 days) and CMV disease (19.7±3.1 days vs. 21.5±4.0 days). The acute allograft rejection incidences were significantly lower with ganciclovir in both asymptomatic CMV replication (8% vs. 14%) and CMV disease (11% vs. 22%). CMV-IEA was detected in renal grafts of patients with acute rejection. There was more CMV-associated acute rejection using acyclovir than using ganciclovir. Except for the higher incidence of anemia leucopenia and anemia with ganciclovir, the safety profiles of both drugs were similar.

CONCLUSIONS: Comprehensive anti-infection solution, mainly with intravenous ganciclovir, can effectively treat CMV infection, shorten duration of therapy, and decrease acute rejection. The few adverse effects had negligible effects on use of ganciclovir.

Keywords: Cytomegalovirus (CMV), renal transplantation, acyclovir, Ganciclovir

Add Comment 0 Comments

In Press

Original article  

The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival Afte...

Ann Transplant In Press; DOI: 10.12659/AOT.945249  

Original article  

Biopsychosocial Effects of Donor Traits on Heart Transplant Recipients

Ann Transplant In Press; DOI:  

Clinical Research  

Ten-Year Retrospective Analysis of Continuous Renal Replacement Therapy in Burn Patients: Impact on Surviva...

Ann Transplant In Press; DOI:  

Original article  

Factors Influencing Stress Disorders in Intensive Care Unit (ICU) Patients After Liver Transplantation: A C...

Ann Transplant In Press; DOI: 10.12659/AOT.944320  

Most Viewed Current Articles

05 Apr 2022 : Original article   13,113

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   10,260

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

12 Jan 2022 : Original article   9,611

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

15 Mar 2022 : Case report   7,271

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358